Off-Label Use of Atypical Antipsychotics: An Update
Summary of Adverse Effects in Elderly Patients (1 of 2)
Antipsychotics increase the risk of death in elderly patients (65 and older) with dementia.
For atypical antipsychotics, the death of 1 in 100 patients can be attributed to the antipsychotic drug. The strength of evidence for this finding is high.
Risperidone is associated with an increased risk of cerebrovascular accidents. One in 34 patients will experience a cerebrovascular accident attributable to risperidone. The strength of evidence for this finding is moderate.
Both risperidone and olanzapine are associated with increased risk of cardiovascular adverse events. For every 53 patients treated, 1 cardiovascular adverse event will occur due to risperidone. For every 48 patients treated, 1 cardiovascular adverse event will occur due to olanzapine. The strength of evidence for these findings is moderate.
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.